Rachit Khandelwal, Pediatrics BMT fellow at Medanta The Medicity, Gurgaon, shared a post on X:
“Targeting CD47: many misses; hopeful for a hit.
In vivo efficacy of a novel, bivalent CD47 immunotoxin used as targeted therapy for T-cell acute lymphoblastic leukemia in a mouse model.”
